Print Page  |  Close Window

SEC Filings

10-Q
BRAINSTORM CELL THERAPEUTICS INC. filed this Form 10-Q on 10/29/2018
Entire Document
 

 

  

BRAINSTORM CELL THERAPEUTICS INC. AND SUBSIDIARIES

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

U.S. dollars in thousands

(Except share data)

 

   Nine months ended   Three months ended 
   September 30,   September 30, 
   2018   2017   2018   2017 
   Unaudited   Unaudited 
                 
Operating expenses:                    
                     
Research and development, net  $4,433   $2,544   $1,975   $1,168 
General and administrative   4,193    2,693    1,257    1,224 
                     
Operating loss   (8,626)   (5,237)   (3,232)   (2,392)
                     
Financial expenses (income), net   (61)   (9)   (56)   11 
                     
Net loss  $(8,565)  $(5,228)  $(3,176)  $(2,403)
                     
Basic and diluted net loss per share from continuing operations  $(0.43)  $(0.28)  $(0.15)  $(0.13)
                     
Weighted average number of shares outstanding used in computing basic and diluted net loss per share   19,754,159    18,737,307    20,691,900    18,783,997 

 

The accompanying notes are an integral part of the consolidated financial statements.

 

 5